Rongchang Biotech: Net profit turns profitable to 709 million yuan by 2025, with rapid growth in domestic sales revenue of core products Taitesi and Vidixtamab.

LightningPacketLoss · 2026-03-05T00:52:48+00:00

Rongchang Biotech recently released its 2025 performance forecast, showing total operating revenue of 3.251 billion yuan, an increase of 89.36% year-on-year; net profit attributable to shareholders was 709 million yuan, turning from loss to profit. The performance growth is mainly attributed to increased sales of core products and collaboration with Vor Biopharma, while cost reduction and management optimization also improved profitability efficiency.

LightningPacketLoss

2026-03-05 00:52:48

Abstract generation in progress

Recently, Rongchang Biotech announced that, according to the 2025 performance forecast, the company achieved a total revenue of 3.251 billion yuan, an increase of 89.36% year-on-year; net profit attributable to shareholders was 709 million yuan, turning from a loss to a profit.

The announcement mentioned that the main reason for the performance change is the rapid growth in domestic sales revenue of the company’s core products, Taituxip and Vedicitumab, which have become the main drivers of performance growth. At the same time, the company successfully reached a significant licensing agreement with Vor Biopharma, resulting in a substantial increase in technology licensing income.

Additionally, through management optimization and process iteration, the unit cost of products decreased, gross profit margin increased, and sales expense ratio significantly declined. Combining these positive factors, the company’s profitability efficiency greatly improved.

(Rongchang Biotech Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.